Anthera Announces First Quarter 2010 Financial Report and Conference Call
HAYWARD, Calif., April 28 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its first quarter 2010 financial report after market close on Thursday, May 6, 2010. Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.
To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The conference ID for the replay is 70784350. The audio replay will be available until May 13, 2010. This conference call will be webcast live and archived on Anthera's website until May 6, 2011, www.anthera.com.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 ready clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.
CONTACT: Juliane Snowden of Burns McClellan, Inc., firstname.lastname@example.org or 212.213.0006
Conference Call Access: Date: May 6, 2010 Time: 5:00 pm Eastern Time Domestic Dial-in: (877) 312-8807 International Dial-in: (253) 237-1190 Passcode: 70784350
SOURCE Anthera Pharmaceuticals, Inc.
You May Also Like